<DOC>
	<DOCNO>NCT01465724</DOCNO>
	<brief_summary>The current prevalence hypertension part metabolic syndrome substantial increase rise obesity worldwide . Chronic elevation sympathetic nervous system ( SNS ) activity identified common key factor disease state obesity-related hypertension ( ORH ) . The renal sympathetic nerve major contributor complex pathophysiology elevate SNS activity . Percutaneous renal denervation ( PRDN ) , deliberate disruption nerve connect kidneys central nervous system , show effective mean modulate elevated SNS activity . This current study observational feasibility study , aim investigate effect renal denervation change insulin resistance blood pressure patient obesity relate hypertension . The investigator study different variable : laboratorial set , set blood pressure measurement set investigation vascular laboratory . Hypothesis - The investigator hypothesize renal denervation beneficial effect insulin resistance . - The investigator hypothesize complication related device procedure .</brief_summary>
	<brief_title>Denervation REnal Artery Metabolic Syndrome</brief_title>
	<detailed_description>Objectives : The objective study : compare change insulin resistance patient ORH RDN ; evaluate safety PRDN patient group ; compare change blood pressure , laboratory parameter , arterial stiffness SNS-activity PRDN . Study design : Prospective observational feasibility-study . Study population : Patients high fast glucose ( fast serum glucose ≥5.6 mmol/L ( 100 mg/dL ) ) ambulatory systolic blood pressure &gt; 130mmHg . Major endpoint : The effect RDN : insulin resistance , blood pressure major adverse event .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients high fast glucose ( fast serum glucose ≥5.6 mmol/L ( ≥100 mg/dL ) ) , without use antidiabetic drug time inclusion AND 24 hour ambulatory SBP &gt; 130 mmHg , without use antihypertensive drug time inclusion . Patients fulfil one criterion meet definition metabolic syndrome . Individual understand study procedure , alternative treatment available , risk involve study voluntarily agree participate give informed consent . Individual 18 year age day sign informed consent . SBP &gt; 180 mmHg and/or DBP &gt; 110 mmHg one screening measurement . 24hour ambulatory SBP &gt; 170 mmHg and/or 24hour ambulatory DBP &gt; 100 mmHg time inclusion . Individual treat one type antihypertensive medication time inclusion . Individual treat one type drug diabetes mellitus 2 time inclusion and/or medication DM type 2 stop . Individual treatable secondary cause hypertension . Individual renal artery anatomy ineligible treatment . Individual estimate glomerular filtration rate ( eGFR ) &lt; 45mL/min/1.73m2 , use MDRD calculation . Individual type 1 diabetes mellitus . Individual experience myocardial infarction , unstable angina pectoris , cerebrovascular accident within 6 month screen visit , widespread atherosclerosis , document intravascular thrombosis unstable plaque . Individual schedule plan surgery cardiovascular intervention next 6 month . Individual hemodynamically significant valvular heart disease reduction BP would consider hazardous . Individual implantable cardioverter defibrillator ( ICD ) pacemaker whose setting allow RF energy delivery . Individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study ( i.e. , patient clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder thrombocytopenia , haemophilia , significant anaemia ) . Individual pregnant , nurse planning pregnant . Individual known , unresolved history drug use alcohol dependency , lack ability comprehend follow instruction , would unlikely unable comply study followup requirement . Individual currently enrol another investigational drug device trial . Individual currently treat follow medication : Drugs cause salt retention ( e.g. , systemic corticosteroid fludrocortisone ) Acenocoumarol phenprocoumon temporarily stop procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>HOMA-IR</keyword>
	<keyword>blood pressure</keyword>
	<keyword>Renal denervation</keyword>
	<keyword>renal sympathetic denervation</keyword>
	<keyword>renal ablation</keyword>
</DOC>